Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: Relationship to glucose disposal
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: Relationship to glucose disposal
复制标题
DOI:
10.1053/meta.2002.50108
复制
发表时间:
2003-05-01
影响因子:
9.8
通讯作者:
Henry, RR
中科院分区:
文献类型:
--
作者:
Mathieu-Costello, O;Kong, A;Henry, RR
The goal of this work was to compare the effects of different antidiabetic therapies on the phenotype of skeletal muscle in type 2 diabetic subjects failing sulfonylurea therapy. Subjects were treated with a thiazolidinedione (troglitazone, TGZ) or a biguanide (metformin, MET) in addition to glyburide for 3 to 4 months. Insulin action was determined with a hyperinsulinemic (300 mU (.) m(-2 .) min(-1)) euglycemic (5.0 to 5.5 mmol/L) clamp. Biopsies were obtained from the vastus lateralis muscle for morphological analysis. Despite similar glycemic control, relative increases in the insulin-stimulated glucose disposal rate (GDR) were greater after TGZ treatment (37 +/- 8% increase, P < .05) than after MET (21 +/- 11%, P < .05). Neither treatment had any effect on fiber type composition of the muscle. Capillary density was reduced in diabetic subjects compared to a nondiabetic group (P < .01) and was increased with TGZ treatment (P < .05), while MET was without significant effect. Diabetic muscle also displayed a lower mitochondrial volume density that was unaltered by either treatment. Both TGZ and MET therapy resulted in a reduction in the lipid content of muscle (percent fiber volume as lipid droplets); the relative decrease tended to be greater for TGZ (-33% v -23% for MET). The relative (%) improvement in GDR was correlated with the change in lipid content (r = -0.756, P